Jump to content

Apraclonidine

From Wikipedia, the free encyclopedia

Apraclonidine
Clinical data
Trade namesIopidine, others
Other namesApraclonidine hydrochloride (JAN JP), Apraclonidine hydrochloride (USAN US)
AHFS/Drugs.comMonograph
MedlinePlusa608005
License data
Routes of
administration
Ophthalmic administration
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
  • US: ℞-only / OTC[1][2]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding98.7%
Elimination half-life8 hours
Identifiers
  • 2,6-Dichloro-N- (4,5-dihydro-1H-imidazol-2-yl) benzene-1,4-diamine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.164.104 Edit this at Wikidata
Chemical and physical data
FormulaC9H10Cl2N4
Molar mass245.11 g·mol−1
3D model (JSmol)
  • Clc1c(c(Cl)cc(N)c1)N/C2=N/CCN2
  • InChI=1S/C9H10Cl2N4/c10-6-3-5(12)4-7(11)8(6)15-9-13-1-2-14-9/h3-4H,1-2,12H2,(H2,13,14,15)
  • Key:IEJXVRYNEISIKR-UHFFFAOYSA-N
  • Key:OTQYGBJVDRBCHC-UHFFFAOYSA-N

Apraclonidine (INN), sold under the brand name Iopidine among others, is a medication used for the treatment of intraocular pressure.[1] It is an alpha-adrenergic agonist.[1] It is used as the salt apraclonidine hydrochloride.[1] It is given by ophthalmic administration.[1]

Medical uses

[edit]

Apraclonidine is indicated to control or prevent post-surgical elevations in intraocular pressure that occur in people after argon laser trabeculoplasty, argon laser iridotomy, or Nd:YAG posterior capsulotomy.[1]

Society and culture

[edit]
[edit]

Apraclonidine was approved for medical use in the United States in 1987.[3]

Names

[edit]

Apraclonidine is sold under the brand names Iopidine and Brytly.[1][2]

References

[edit]
  1. 1 2 3 4 5 6 7 "Iopidine 1%- apraclonidine hydrochloride ophthalmic solution solution/ drops". DailyMed. 8 May 2026. Retrieved 17 October 2026.
  2. 1 2 "Brytly- apraclonidine hydrochloride solution/ drops". DailyMed. 28 October 2026. Retrieved 4 November 2026.
  3. ↑ "Iopidine: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 17 October 2026.

Further reading

[edit]
  • Chen PL, Chen JT, Lu DW, Chen YC, Hsiao CH (June 2006). "Comparing efficacies of 0.5% apraclonidine with 4% cocaine in the diagnosis of horner syndrome in pediatric patients". Journal of Ocular Pharmacology and Therapeutics. 22 (3): 182–187. doi:10.1089/jop.2006.22.182. PMID 16808679.
  • Aslanides M, Tsiklis NS, Ozkilic E, Coskunseven E, Pallikaris G, Jankov MR (June 2006). "The effect of topical apraclonidine on subconjunctival hemorrhage and flap adherence in LASIK patients". Journal of Refractive Surgery. 22 (6): 585–588. doi:10.3928/1081-597X-20060601-11. PMID 16805122.
  • Koc F, Kansu T, Kavuncu S, Firat E (March 2006). "Topical apraclonidine testing discloses pupillary sympathetic denervation in diabetic patients". Journal of Neuro-Ophthalmology. 26 (1): 25–29. doi:10.1097/01.wno.0000204648.79744.71. PMID 16518162. S2CID 45290834.
  • Garibaldi DC, Hindman HB, Grant MP, Iliff NT, Merbs SL (2006). "Effect of 0.5% apraclonidine on ptosis in Horner syndrome". Ophthalmic Plastic and Reconstructive Surgery. 22 (1): 53–55. doi:10.1097/01.iop.0000196322.05586.6a. PMID 16418668.
  • Onal S, Gozum N, Gucukoglu A (2005). "Effect of apraclonidine versus dorzolamide on intraocular pressure after phacoemulsification". Ophthalmic Surgery, Lasers & Imaging. 36 (6): 457–462. doi:10.3928/1542-8877-20051101-05. PMID 16355950.
[edit]